<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316936</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT04316936</nct_id>
  </id_info>
  <brief_title>Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery</brief_title>
  <official_title>Evaluation of Efficacy in the Resolution of Post-Operative Inflammation and Pain in Patients Receiving Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silverstein Eye Centers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Silverstein Eye Centers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and
      Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain
      following cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized trial where patients will be randomly assigned to 1 of 3 groups, each
      with a sample size of 25 (total n=75). Group 1 will receive DEXYCU + Omidria (Omidria =
      ketorolac + phenylephrine), group 2 will receive DEXTENZA + Omidria, and group 3 will receive
      prednisolone acetate + Omidria. Each of the drug combinations used in each of the 3 groups is
      standard of care, FDA approved, and will be used on label. 1:1:1, n=75 with 25 subjects
      assigned to each of the 3 groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to 1 of 3 groups (1:1:1), each with a sample size of 25 (total n=75). Group 1 will receive DEXYCU + Omidria (Omidria = ketorolac + phenylephrine), group 2 will receive DEXTENZA + Omidria, and group 3 will receive prednisolone acetate + Omidria.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of anterior chamber inflammation</measure>
    <time_frame>Assessed at day 8 post-operatively</time_frame>
    <description>The primary efficacy end point is the complete resolution of anterior chamber inflammation (cell and flare). This is a non-contact, non-invasive test performed by the physician using a slit lamp. The evaluation requires less than one minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of anterior chamber inflammation</measure>
    <time_frame>Assessed at day 15 post-operatively</time_frame>
    <description>The primary efficacy end point is the complete resolution of anterior chamber inflammation (cell and flare). This is a non-contact, non-invasive test performed by the physician using a slit lamp. The evaluation requires less than one minute.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resolution of anterior chamber inflammation</measure>
    <time_frame>Assessed at day 30 post-operatively</time_frame>
    <description>The primary efficacy end point is the complete resolution of anterior chamber inflammation (cell and flare). This is a non-contact, non-invasive test performed by the physician using a slit lamp. The evaluation requires less than one minute.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of postoperative pain</measure>
    <time_frame>Assessed at day 1 post-operatively</time_frame>
    <description>The secondary efficacy endpoint is the elimination of post-operative pain per a subjective, standardized scale. Post-operative pain as measured on a scale from 0-10 (ocular pain assessment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of postoperative pain</measure>
    <time_frame>Assessed at day 8 post-operatively</time_frame>
    <description>The secondary efficacy endpoint is the elimination of post-operative pain per a subjective, standardized scale. Post-operative pain as measured on a scale from 0-10 (ocular pain assessment).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Optical Coherence Tomography (OCT)</measure>
    <time_frame>Assessed pre-operatively and 1 month post-operatively</time_frame>
    <description>OCT is a non-contact, non-invasive test that takes less than a minute to perform. All that is required of the patient is that they sit still and look at a fixation light while the machine takes a picture. No eye drops or any other intervention are required. OCT scanning will provide an image of the deep layers of the retina and will be used to determine macular thickness measurement (macular thickness has been correlated to changes in contrast sensitivity) before and 30 days following surgery. .</description>
  </other_outcome>
  <other_outcome>
    <measure>Contrast sensitivity testing</measure>
    <time_frame>Assessed pre-operatively, and at 15 days and 30 days post-operatively</time_frame>
    <description>This test is non-contact, non-invasive and used to distinguish between finer and finer increments of light versus dark. The patient simply looks at a chart similar to the Snellen Eye Chart and distinguishes lighter shades from darker shades. The test is performed in less than one minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>Assessed pre-operatively, and at 15 days and 30 days post-operatively</time_frame>
    <description>ETDRS chart at 4m</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical Coherence Tomography (OCT)</measure>
    <time_frame>Assessed pre-operatively and 1 month post-operatively</time_frame>
    <description>OCT is a non-contact, non-invasive test that takes less than a minute to perform. All that is required of the patient is that they sit still and look at a fixation light while the machine takes a picture. No eye drops or any other intervention are required. OCT scanning will provide an image of the deep layers of the retina and will be used to evaluate for the presence of cystoid macular edema before and 30 days following surgery.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omidria (= ketorolac + phenylephrine) and intracanalicular dexamethasone insert (punctal plug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omidria + Dexycu</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omidria (= ketorolac + phenylephrine) and intraocular dexamethasone suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omidria + Prednisolone Acetate 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omidria (= ketorolac + phenylephrine) and topical prednisolone acetate ophthalmic drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omidria</intervention_name>
    <description>phenylephrine 1% and ketorolac 0.3% intraocular solution</description>
    <arm_group_label>Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg</arm_group_label>
    <arm_group_label>Omidria + Dexycu</arm_group_label>
    <arm_group_label>Omidria + Prednisolone Acetate 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza (dexamethasone ophthalmic insert) 0.4mg</intervention_name>
    <description>intracanalicular dexamethasone insert</description>
    <arm_group_label>Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexycu, 9% Intraocular Suspension</intervention_name>
    <description>dexamethasone intraocular suspension</description>
    <arm_group_label>Omidria + Dexycu</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate 1%</intervention_name>
    <description>standard postoperative ophthalmic drop regimen</description>
    <arm_group_label>Omidria + Prednisolone Acetate 1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age or older, undergoing routine, uncomplicated cataract surgery.

        Exclusion Criteria:

          -  Any history of corneal dystrophy, corneal surgery within 6 months of cataract surgery,
             previous intraocular surgery, any concomitant eye drop use besides artificial tears,
             previous ocular trauma, or a history of treated glaucoma. No additional procedures can
             be done at the time of cataract surgery (e.g., stent placement, endo-laser, etc.), but
             femto-second laser-assisted surgery is permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Bentley</last_name>
      <phone>816-595-3958</phone>
      <email>cbentley@silversteineyecenters.com</email>
    </contact>
    <investigator>
      <last_name>Steven Silverstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dextenza</keyword>
  <keyword>intracanalicular dexamethasone</keyword>
  <keyword>dexamethasone ophthalmic insert</keyword>
  <keyword>Dexycu</keyword>
  <keyword>Omidria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

